Showing results (1851-1860 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 24, 2022
Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancerHisao Imai, Yoshiaki Nagai, Hiroyuki Minemura, et al.
Investigational New Drugs|June 27, 2022
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumorsNabil Adra, David J Vaughn, Lawrence H Einhorn, et al.
Investigational New Drugs|January 1, 1986
Biological and biochemical activities of the novel antitumor antibiotic PD 114,759 and related derivativesD W Fry, J L Shillis, W R Leopold
Investigational New Drugs|May 25, 2019
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumoursTakahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, et al.
Investigational New Drugs|October 11, 2021
Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinomaXia Yuan, Yi He, Chenhui Luo, et al.
Investigational New Drugs|June 2, 2019
Phase II study of avelumab in multiple relapsed/refractory germ cell cancerM Mego, D Svetlovska, M Chovanec, et al.
Investigational New Drugs|January 1, 1985
Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometryR Ganapathi, P Gulick, R Miller, et al.
Investigational New Drugs|January 1, 1985
Mitoxantrone in the treatment of relapsed and refractory acute leukemiaP Meyer, A D Ho, G Ehninger, et al.
Investigational New Drugs|April 18, 2022
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skinLuke S McLean, Tessa A Morris, Ann Gramza, et al.
Investigational New Drugs|April 18, 2022
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysisYunxia Tao, Yu Zhou, Le Tang, et al.
Pageof 372